FindMyKOL

Lazaros Nikolaidis, MD

Basic profile

Baylor Scott & White Medical Center - Temple

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionTemple, TX · South CentralSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLEmergingFindMyKOL type: RegionalLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Lazaros Nikolaidis is a Cardiology physician affiliated with Baylor Scott & White Medical Center - Temple. OpenAlex indexes 59 publications with 3,403 citations (h-index 16).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
59publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

3,403citations

Citations across these publications.

16h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
16companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Janssen Scientific Affairs, LLC
    Program year20251 payment
    $63
  • CVRx, Inc.
    Program year20251 payment
    $51
  • Abbott Laboratories
    Program year20251 payment
    $50
All 38 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    76.1%
    Beta blocker15.3%
    Metoprolol Succinate50%Carvedilol38%Bisoprolol Fumarate12%
    Part D≥91 patients
    Aldosterone antagonist (MRA)13.4%
    Spironolactone83%Eplerenone17%
    Part D≥138 patients

    + 14 more classes in this area

  • Metabolism & gastrointestinal

    16.7%
    SGLT2 inhibitor12.2%
    Jardiance62%Farxiga38%
    Part D≥78 patients
    GLP-1 receptor agonist1.9%
    Ozempic100%
    Part D≥23 patients

    + 3 more classes in this area

  • Blood & clotting

    4%
    Factor Xa inhibitor2.5%
    Eliquis100%
    Part D≥28 patients
    P2Y12 inhibitor1.5%
    Clopidogrel100%
    Part D≥21 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”